• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessment of gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.

作者信息

Nicoś Marcin, Wojas-Krawczyk Kamila, Krawczyk Paweł, Chmielewska Izabela, Wojcik-Superczyńska Magdalena, Reszka Katarzyna, Kieszko Robert, Góra-Florek Anna, Dudek Małgorzata, Świniuch Daria, Papiewski Wojciech, Całka Paulina, Ciesielka Marzanna, Ramlau Rodryg, Milanowski Janusz

机构信息

Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.

Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

出版信息

Arch Med Sci. 2019 Nov 3;16(6):1496-1500. doi: 10.5114/aoms.2019.89217. eCollection 2020.

DOI:10.5114/aoms.2019.89217
PMID:33224359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7667428/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f86c/7667428/0a2c3be6e90e/AMS-16-6-38386-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f86c/7667428/cabe32218048/AMS-16-6-38386-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f86c/7667428/0a2c3be6e90e/AMS-16-6-38386-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f86c/7667428/cabe32218048/AMS-16-6-38386-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f86c/7667428/0a2c3be6e90e/AMS-16-6-38386-g002.jpg

相似文献

1
Assessment of gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.评估循环游离DNA中的基因突变在监测肺腺癌患者对表皮生长因子受体酪氨酸激酶抑制剂反应中的作用
Arch Med Sci. 2019 Nov 3;16(6):1496-1500. doi: 10.5114/aoms.2019.89217. eCollection 2020.
2
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.基于皮升液滴数字聚合酶链反应的游离血浆DNA分析，以评估肺腺癌中对酪氨酸激酶抑制剂产生耐药性的表皮生长因子受体突变
Oncologist. 2016 Feb;21(2):156-64. doi: 10.1634/theoncologist.2015-0288. Epub 2016 Jan 14.
3
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.血浆循环肿瘤 DNA 中 EGFR 突变的检测作为晚期肺腺癌患者一线吉非替尼治疗的选择标准（BENEFIT）：一项 2 期、单臂、多中心临床试验。
Lancet Respir Med. 2018 Sep;6(9):681-690. doi: 10.1016/S2213-2600(18)30264-9. Epub 2018 Jul 17.
4
[Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].[晚期肺腺癌患者血浆中表皮生长因子受体突变的相对丰度预测对表皮生长因子受体-酪氨酸激酶抑制剂的临床反应]
Zhonghua Nei Ke Za Zhi. 2019 Jan 1;58(1):49-55. doi: 10.3760/cma.j.issn.0578-1426.2019.01.009.
5
[Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].[液滴数字PCR与超级扩增阻滞突变系统检测晚期肺腺癌患者血浆循环肿瘤DNA中表皮生长因子受体基因突变的临床价值]
Zhongguo Fei Ai Za Zhi. 2020 Feb 20;23(2):84-90. doi: 10.3779/j.issn.1009-3419.2020.02.03.
6
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.表皮生长因子受体基因表达水平对接受一线表皮生长因子受体-酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型肺腺癌患者临床结局的影响。
Tumour Biol. 2017 Mar;39(3):1010428317695939. doi: 10.1177/1010428317695939.
7
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
8
Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.表皮生长因子受体酪氨酸激酶抑制剂治疗 EGFR 突变从不吸烟肺腺癌患者的反应持续时间预测。
Lung Cancer. 2014 Mar;83(3):374-82. doi: 10.1016/j.lungcan.2013.12.011. Epub 2014 Jan 3.
9
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.表皮生长因子受体酪氨酸激酶结构域的突变是预测和预后非小细胞肺癌患者吉非替尼治疗效果的一个因素。
Clin Cancer Res. 2005 May 15;11(10):3750-7. doi: 10.1158/1078-0432.CCR-04-1981.
10
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.吸烟对携带激活型表皮生长因子受体（EGFR）突变的肺腺癌患者表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂治疗反应的影响。
Lung Cancer. 2014 May;84(2):196-202. doi: 10.1016/j.lungcan.2014.01.022. Epub 2014 Feb 3.

引用本文的文献

1
The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.液体活检在非小细胞肺癌临床应用中的观点概述
Life (Basel). 2022 Oct 19;12(10):1640. doi: 10.3390/life12101640.

本文引用的文献

1
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study.数字PCR检测晚期肺腺癌患者低水平表皮生长因子受体（EGFR）突变的评估：一项跨平台比较研究
Oncotarget. 2017 Jun 29;8(40):67810-67820. doi: 10.18632/oncotarget.18866. eCollection 2017 Sep 15.
2
Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients.血浆中表皮生长因子受体（EGFR）突变的动态变化概括了非小细胞肺癌（NSCLC）患者对EGFR酪氨酸激酶抑制剂（EGFR-TKIs）的临床反应。
Oncotarget. 2017 Jul 10;8(38):63846-63856. doi: 10.18632/oncotarget.19139. eCollection 2017 Sep 8.
3
Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC.
采用液滴数字PCR检测非小细胞肺癌中循环游离DNA中突变型EGFR L858R和外显子19浓度与EGFR-TKIs反应的相关性。
Oncol Lett. 2017 Aug;14(2):2573-2579. doi: 10.3892/ol.2017.6425. Epub 2017 Jun 20.
4
Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.循环肿瘤 DNA 水平与非小细胞肺癌酪氨酸激酶抑制剂 (TKI) 治疗反应的相关性。
Med Sci Monit. 2017 Jul 25;23:3627-3634. doi: 10.12659/msm.902265.
5
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.游离循环表皮生长因子受体（EGFR）突变浓度的评估可预测接受EGFR酪氨酸激酶抑制剂（EGFR-TKIs）治疗的非小细胞肺癌（NSCLC）患者的预后。
Oncotarget. 2017 Feb 21;8(8):13195-13205. doi: 10.18632/oncotarget.14490.
6
Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者循环肿瘤DNA的检测
Oncotarget. 2017 Jan 10;8(2):2130-2140. doi: 10.18632/oncotarget.12883.
7
Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.检测循环血浆 DNA 突变分析以确定肺腺癌患者对表皮生长因子受体酪氨酸激酶抑制剂治疗的反应。
Sci Rep. 2016 Sep 19;6:33505. doi: 10.1038/srep33505.
8
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.一项前瞻性临床试验中，对EGFR-L858R突变型肺癌患者进行EGFR-TKI治疗反应和耐药性的循环游离DNA（cfDNA）连续评估。
J Hematol Oncol. 2016 Sep 13;9(1):86. doi: 10.1186/s13045-016-0316-8.
9
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.ctDNA 检测在欧洲和日本晚期 NSCLC 患者中 EGFR 基因突变状态：ASSESS 研究。
J Thorac Oncol. 2016 Oct;11(10):1682-9. doi: 10.1016/j.jtho.2016.05.036. Epub 2016 Jul 25.
10
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.血浆表皮生长因子受体（EGFR）T790M循环肿瘤DNA（ctDNA）状态与获得性EGFR酪氨酸激酶抑制剂（TKI）耐药的晚期非小细胞肺癌（NSCLC）患者的临床结局相关。
Sci Rep. 2016 Feb 12;6:20913. doi: 10.1038/srep20913.